Bora Pharmaceuticals Wins Dual Honors at the Taiwan MAPECT M&A Ceremony: “Deal of the Year” Award and “Best Cross-Border M&A” Award
December 11, 2024 —The Taiwan Mergers & Acquisition and Private Equity Council announced its winners today in the MAPECT Award Ceremony. Among 149 M&A cases, Bora Pharmaceuticals distinguished itself by winning both the “Deal of the Year” Award and the “Best Cross-Border M&A” Award, showcasing Bora’s exceptional achievements in M&A strategy and global market expansion.
The selection panel praised Bora as Taiwan’s first large-scale pharmaceutical company to make significant inroads into the U.S. market, and for the synergies demonstrated through its acquisition efforts. Through the acquisition of Upsher-Smith Laboratories (USL), Bora successfully overcame key barriers to enter the world’s largest pharmaceutical market. This acquisition expanded its pediatric neurology product line with VIGADRONE® (vigabatrin).
In addition, Bora achieved significant operational synergies in July when USL and TWi Pharmaceuticals completed its logistics integration, transferring TWi USA’s third-party logistics operations to USL’s in-house warehouse. This move significantly improved the Company’s distribution efficiency, reduced management costs, and accelerated revenue growth.
Bora Group Chairman Bobby Sheng stated: “The post-merger integration process has demonstrated our ability to swiftly adapt and strengthen our Company operation, with long-term operational benefits gradually becoming evident. Our recently acquired sterile injectable fill/finish facility in Baltimore has also embarked on a two-month equipment upgrade program in November. Once completed, the facility will comply with the latest EU GMP Annex 1 standards. This will not only solidify Bora’s presence in the U.S. CDMO market but also create new opportunities to be a valued partner for our clients in the European market, significantly enhancing our global competitiveness.”
Looking ahead, Bora will continue to deepen its global business footprint through its dual engine strategy of CDMO and global commercial sales operations. Driven by innovation and operational efficiency, the Company aims to become a leader in the global pharmaceutical industry.
About Bora
Founded in 2007, Bora Pharmaceutical Co., Ltd. (“Bora” or “the Company”, 6472.TW) is the largest pharmaceutical manufacturer in Taiwan with well-connected global distribution to supply more than 100 countries around the world. With headquarters in Taiwan, Bora has dedicated itself to becoming a global contender by executing strategic plans for Research and Development, Production, Sales, and Marketing in parallel. The Company’s commitment to quality, efficiency, and fully-customized management ensures the most value-added services for all customers. As part of its core global CDMO business, Bora owns and operates ten state-of-the-art cGMP manufacturing facilities in Taiwan, Canada, and the US, built to the highest international standards for manufacturing, packaging, R&D, and analytical testing. Bora continues to expand its capacity and capability to serve customers through the prudent execution of its merger and acquisition strategy.
Investor/Media Inquiries
Wynne Ho, Investor relation Manager
+886 2 790-1555 Ext. 9418
Email：wynne.ho@bora-corp.com
